Topics and Speakers:
Including China into Your Drug Development Strategy: Why, When and How?
Jiansong Yang, PhD, CSO, Tigermed
Dr. Jiansong Yang is the Chief Scientific Officer of Tigermed, which is the largest clinical CRO in China. He’s also the Founder and CEO of Mosim (acquired by Tigermed company), which focuses on drug development strategy, clinical study design, and PK/PD data analysis.
Dr. Yang has over 15 years of experience in the pharmaceutical industry, specializing in early drug development and clinical study design. Prior to Mosim, he was Director of Clinical Pharmacology at GSK. He received his Ph.D. in Clinical Pharmacokinetics from the University of Sheffield, UK.
The Future of Global Drug Development Beyond the Pandemic
Amir Kalali, MD, Chairman, CNS Summit
Dr. Amir Kalali is a physician scientist, recognized globally as a leading innovator at the intersection of life sciences and technology, and a convener of collaborative high impact forums. He is the Chairman and Chief Curator of the CNS Summit, a forum focused on the future of life sciences, and was the Founding Chairman, and sits on the Executive Committee of the International Society for CNS Drug Development (ISCDD), one of the first independent non-profits to bring together leaders in drug development to collaborate. He has been involved in initiatives by the Institute of Medicine, as well as the NIH FAST and the NIH NCATS program. Previously, he was the Global Head of the Neuroscience Center of Excellence at Quintiles, now known as IQVIA. In this role, he was responsible for numerous successful drug development programs. He is a Professor of Psychiatry at the University of California San Diego, Editor of the journal Innovations in Clinical Neuroscience, and the Lead Editor of the book Essential CNS Drug Development. Dr. Kalali sits on the board of directors of both private and publicly traded companies and advises companies in the life sciences and technology sectors, universities, and the investment groups.
